Nilo Therapeutics
Nilo Therapeutics Raises $101M in Series A
Quick Facts
Nilo Therapeutics Raises $101M in Series A
Nilo Therapeutics has successfully raised $101M in a Series A at a $400M valuation led by The Column Group, DCVC Bio, Lux Capital, Gates Foundation.
Company Overview
Nilo Therapeutics is a Biotech company headquartered in New York, NY, founded in 2025 with 30+ employees.
Developing therapies targeting neural circuits for immune disease regulation
Fundraising Details
- Amount Raised: $101M
- Round Type: Series A
- Valuation: $400M
- Date: 2025-10-08
- Investors: The Column Group, DCVC Bio, Lux Capital, Gates Foundation
About Nilo Therapeutics
Developing therapies targeting neural circuits for immune disease regulation The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: New York, NY
- Founded: 2025
- Team Size: 30+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Nilo Therapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Nilo Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $400M valuation marks an important milestone for Nilo Therapeutics, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Nilo Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-10-08. For more information about Nilo Therapeutics, visit their headquarters at New York, NY.
About the Author
Related Company Reports
Harvey AI Raises $160 million in Series F
Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.
7AI Raises $130 million in Series A
7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.
TRIANA Biomedicines Raises $120 million in Series B
TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.